ArticleFrontiers in oncology2023

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption.

Sarah Morin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.